Non-Alcoholic Steatohepatitis Market Is Expected To Reach Worth US$ 20,676.0 Mn By 2025 | Credence Research
According to the latest report published by Credence Research, Inc. “Non-Alcoholic Steatohepatitis Market — (Drug Type — Obeticholic Acid, Aramchol, Saroglitazar and Elafibranors): Market Growth, Future Prospects and Competitive Analysis, 2017–2025,” the market was valued at US$ 729.0 Mn in 2016, and is expected to reach US$ 20,676.0 Mn by 2025, expanding at a CAGR of 46.1% from 2017 to 2025.
Browse the full report at https://www.credenceresearch.com/report/non-alcoholic-steatohepatitis-market
Nonalcoholic Steatohepatitis (NASH) is the progressive form of Nonalcoholic Fatty Liver Disease (NAFLD), wherein excessive fat deposition causes inflammation and damage to the liver, eventually leading to cirrhosis and increasing risk of liver failure and hepatocellular carcinoma in some cases. NASH affects around 2–5% of Americans and is considered to be one of the foremost causes of liver transplantation. Currently management of NASH includes lifestyle changes such as healthy diet, weight reduction and physical activity. Despite of growing treatment need there are no approved therapeutic for NASH. Some drugs are prescribed off-label such as Metformin which is used in type-2 diabetes and NASH. However, NASH therapeutics exhibit a lucrative pipeline with more than 20 drug candidates undergoing Phase II clinical trials. The most promising drug anticipated to enter the NASH market in the near future is Elafibranor (Genfit) and Obeticholic Acid (Intercept) which are undergoing phase III trials. Many pharma giants Allergan, Gilead Sciences, Novo Nordisk and Bristol-Myers Squibb are developing drugs for NASH which further boost the NASH market during the future period.
North America held the largest share in the global non-alcoholic steatohepatitis market. In U.S. more than 25% of the population is affected by NAFLD as mentioned by the America Liver Foundation. Moreover, the rate of obesity is increasing rapidly in the children and adult in the U.S. which is a primary risk factor for NASH. Furthermore, aggressive research and clinical trials in the region would further boost the non-alcoholic steatohepatitis market. According to the British Liver Trust, Non-Alcoholic Fatty Liver Disease (NAFLD) is considered to be the most common liver problem in the Western world, affecting 20–30% of the population. Asia Pacific is one of the fastest growing NASH market due to alarming increase in the obesity rates in the region due to rising lifestyle changes. Moreover, the increasing number of research & development and supportive regulations are favouring the growth of non-alcohol steatohepatitis market.
Market Competition Assessment:
The non-alcoholic steatohepatitis market has major pharmaceutical companies such as Gilead Sciences, Novo Nordisk, and Bristol-Myers Squibb developing drugs for NASH or its consequences, with Allergan the latest to enter the space. Allergan acquired Tobira Therapeutics Inc. and Akarna Therapeutics Ltd. in the second half of 2016. These acquisitions provide Allergan a readymade pipeline for the potentially lucrative NASH market.
Key Market Movements:
- Lucrative pipeline for NASH market with more than 20 molecules undergoing clinical trials would boost the demand for NASH market.
- Alarming rise in the diabetes and obesity prevalence would act as a driving factor for the growth of the NASH market.
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58580
Table of Content
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I — Secondary Research
1.3.2 Phase II — Primary Research
1.3.3 Phase III — Expert Panel Review
Chapter 2 Executive Summary
2.1 Non-Alcoholic Steatohepatitis Market Portraiture
2.2 Non-Alcoholic Steatohepatitis Market, by Drug Type, 2016 (US$ Mn)
2.3 Non-Alcoholic Steatohepatitis Market, by Geography, 2016 (Value %)
Chapter 3 Global Non-Alcoholic Steatohepatitis Market Analysis
3.1 Global Non-Alcoholic Steatohepatitis Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
188.8.131.52 Lucrative Pipeline for NASH Therapeutics
184.108.40.206 Alarming rise in the diabetic and Obese Population Globally
220.127.116.11 High Prices of the drug considering the long duration of the treatment
18.104.22.168 Minimum Diagnostic Techniques for NASH
22.214.171.124 NASH Biomarker Development
3.3 Attractive Investment Proposition
3.4 Competitive Analysis: Global Non-Alcoholic Steatohepatitis Market, 2016 (Value %)
Chapter 4 Global Non-Alcoholic Steatohepatitis Market Analysis, By Drug Type
4.1.1 Market Attractive Proposition of Non-Alcoholic Steatohepatitis Market, by Drug Type, 2016
4.2 Obeticholic Acid
Chapter 5 Global Non-Alcoholic Steatohepatitis Market, By Geography
5.2 North America (U.S. & Canada)
5.2.1 North America Non-Alcoholic Steatohepatitis Market, by Drug Type, 20152025 (US$ Mn)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Non-Alcoholic Steatohepatitis Market, by Drug Type, 2015–2025 (US$ Mn)
5.4 Asia-Pacific (China, Japan & Rest of Asia-Pacific)
5.4.1 Asia Pacific Non-Alcoholic Steatohepatitis Market, by Drug Type, 20152025 (US$ Mn)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Non-Alcoholic Steatohepatitis Market, by Drug Type, 20152025 (US$ Mn)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Non-Alcoholic Steatohepatitis Market, by Drug Type, 2015–2025 (US$ Mn)
Chapter 6 Company Profiles
6.1 AstraZeneca plc
6.2 Intercept Pharmaceutical Inc.
6.3 Galmed Pharmaceuticals
6.4 GENFIT SA
6.6 Gilead Science Inc.
6.7 Zydus Cadila
6.8 Immuron Ltd.
6.9 Conatus Pharmaceuticals
6.10 Novo Nordisk
6.11 Enzo Biochem, Inc.
6.12 Raptor Pharmaceuticals
Do Inquiry before Buying for research report: https://www.credenceresearch.com/inquiry-before-buying/58580